Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 201335 NA in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02182297
Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C] BI 1356 as oral (p.o.) solutionDrug: [14C] BI 1356 solution for i.v. infusion
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02183610
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT02183181
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 66
- Registration Number
- NCT02182674
BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Low dose of BI 1356 BSDrug: Medium dose of BI 1356 BSDrug: High dose of BI 1356 BSDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT02183324
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Phase 2
Terminated
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7
- Registration Number
- NCT02182869
Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ESR 1150 CL, Capsule, oralDrug: ESR 1150 CL, solution, intravenous
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02183259
Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02183506
Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT02182700
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1309
- Registration Number
- NCT02183064